Drug intelligence / Profile preview

OcuNASE

Development stage: Preclinical
Lead developer: cellNUA
Administration: Intranasal, Ophthalmic, Topical

Overview

OcuNASE is a bio-mimetic mucosal prophylactic barrier spray developed by cellNUA and its commercial partner Cellnutrition. Developed using cellNUA's proprietary BEEMAR platform, which combines honeybee-derived enzymes (such as lysozyme) with marine plasma, OcuNASE is designed as a 3-in-1 barrier spray for the eyes, nose, and throat. It forms a protective physical and biological barrier on mucosal surfaces to prevent the entry of broad mucosal pathogens, specifically targeting seasonal influenza and emerging coronaviruses. The product is positioned for commercial launch in 2026.

Brand names: OcuNASE

Beyond the preview

Go deeper on OcuNASE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OcuNASE.

Explore the full profile